Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Medications

Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial

C. Le Roux; D. C. W. Lau; A. Astrup; K. Fujioka; F. Greenway; A. Halpern; M. Krempf; R. Violante Ortiz; J. P. H. Wilding; C. B. Jensen; et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial Diabetologia

Early responders to liraglutide 3.0mg as adjunct to diet and exercise from the SCALE

C. W. Le Roux; S. Wharton; S. K. Lilleore; C. H. Jepsen; L. J. Aronne Early responders to liraglutide 3.0mg as adjunct to diet and exercise from the SCALE Diabetic medicine

Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors: SCALE obesity and prediabetes randomised, double-blind, placebo-controlled 3-year trial

C. W. Le Roux; A. Astrup; F. Greenway; M. Krempf; R. Vettor; L. Shapiro Manning; S. K. Lilleore; K. Fujioka Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors: SCALE obesity and prediabetes randomised, double-blind, placebo-controlled 3-year trial Diabetologia
Insulin Resistance & Diabetes

Once-weekly semaglutide 2.4 mg improved metabolic syndrome in adults with overweight or obesity: post-hoc analysis of the STEP 1 Trial

C. W. Le Roux; M. Davies; J. P. Frias; P. N. Laursen; I. Lingvay; S. Machineni; A. Varbo; J. P. Wilding; S. O. Wallenstein; L. Perreault Once-weekly semaglutide 2.4 mg improved metabolic syndrome in adults with overweight or obesity: post-hoc analysis of the STEP 1 Trial Obesity facts
Metabolic Syndrome

Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes

C. W. Le Roux; D. C. W. Lau; K. Fujioka; F. Greenway; J. P. H. Wilding; P. B. Jacobsen; T. Skjoth; S. Madsbad Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes Diabetic medicine
Insulin Resistance & Diabetes

Liraglutide; A new hope for obese diabetics

A. Kumar; D. Kumar; S. Razzaque; A. Kumar; R. Kumar; M. I. Ghauri; M. Yaseen Liraglutide; A new hope for obese diabetics Journal of the Liaquat University of Medical and Health Sciences
Insulin Resistance & Diabetes

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

C. W. le Roux; A. Astrup; K. Fujioka; F. Greenway; D. C. W. Lau; L. Van Gaal; R. V. Ortiz; J. P. H. Wilding; T. V. Skjøth; L. S. Manning; X. Pi-Sunyer 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial Lancet
Insulin Resistance & Diabetes

Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?

A. Kokkinos; D. Tsilingiris; C. W. le Roux; F. Rubino; C. S. Mantzoros Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery? Metabolism
Insulin Resistance & Diabetes

Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial

D. S. Feig; L. E. Donovan; B. Zinman; J. J. Sanchez; E. Asztalos; E. A. Ryan; I. G. Fantus; E. Hutton; A. B. Armson; L. L. Lipscombe; D. Simmons; J. F. R. Barrett; P. J. Karanicolas; S. Tobin; H. D. McIntyre; S. Y. Tian; G. Tomlinson; K. E. Murphy; D. Fei Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial The Lancet Diabetes and Endocrinology
Insulin Resistance & Diabetes

Liraglutide Does Not Adversely Impact Fat-Free Mass Loss

A. Grannell; W. P. Martin; B. Dehestani; W. Al-Najim; J. C. Murphy; C. W. le Roux Liraglutide Does Not Adversely Impact Fat-Free Mass Loss Obesity (Silver Spring)

Older posts

Newer posts

← Previous Page1 … Page20 Page21 Page22 … Page27 Next →

Search for:

Recent Posts

10th ASOI Annual Scientific Meeting 2026
9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2026 ASOI